Cambium Bio Says US FDA Approves Potency Assay Strategy for Eye Disease Drug Candidate

MT NewswiresMar 18 02:39 ET

Cambium Bio Ltd: Half Year Report and Accounts

ASXFeb 27 02:25 ET · Announcements

Cambium Jumps 43% as FDA Approves Phase 3 Trial for Elate Ocular

The Market HeraldFeb 24 19:37 ET

Press Release: Cambium Bio Successfully Closes A$3.0M Financing Round

Dow JonesDec 4, 2024 22:58 ET

Cambium Bio Ltd: Cambium 4E and Annual Report

Aug 30, 2024 00:27 ET · Announcements

Cambium Bio Limited's Stake in Regeneus Diluted

TipRanksJul 18, 2024 21:17 ET